02.24.15
NuGene International has formed a new division to focus specifically on stem cell derived treatments that may require FDA approval.
"NuGene is realizing outstanding progress with its skin and hair care products," explained Ali Kharazmi CEO of NuGene. "We now want to deliver our technology to the next level. NuGene BioPharma will seek to acquire and develop intellectual property and products that, subject to FDA approval, treat various conditions based upon stem cell technology that we have already created and are currently marketing."
The company markets and sells a variety of cosmeceutical products based on adipose derived human stem cells and human stem cell media. NuGene has carefully developed its line of products based upon proprietary stem cell technology and intends to expand this into a line of FDA approved pharmaceuticals.
"There are many applications for our stem cell technology that could relieve skin conditions such as burns and acne," continued Kharazmi. "This topical segment of the pharmaceutical industry is a natural extension of our current operations, and we are evaluating near term opportunities that could integrate our technology with currently approved treatments. We will continue to explore avenues that can extend our brand and diversify our revenue streams to add shareholder value."
"NuGene is realizing outstanding progress with its skin and hair care products," explained Ali Kharazmi CEO of NuGene. "We now want to deliver our technology to the next level. NuGene BioPharma will seek to acquire and develop intellectual property and products that, subject to FDA approval, treat various conditions based upon stem cell technology that we have already created and are currently marketing."
The company markets and sells a variety of cosmeceutical products based on adipose derived human stem cells and human stem cell media. NuGene has carefully developed its line of products based upon proprietary stem cell technology and intends to expand this into a line of FDA approved pharmaceuticals.
"There are many applications for our stem cell technology that could relieve skin conditions such as burns and acne," continued Kharazmi. "This topical segment of the pharmaceutical industry is a natural extension of our current operations, and we are evaluating near term opportunities that could integrate our technology with currently approved treatments. We will continue to explore avenues that can extend our brand and diversify our revenue streams to add shareholder value."